Strength in healthcare and financial stocks has kept the ASX on life support, retaining some gains to lift 0.21pc overall.

Canaccord's Tim Hoff saw Azure Minerals coming before it happened. He thinks Zambian copper junior Prospect has similar credentials.

A home-grown leader in sleep and neural analysis, Compumedics is tackling the burgeoning US home sleep testing market.

Meteoric Resources has been up to 36.3% higher after releasing a maiden resource estimate for the Bara do Pacu licence at its Caldeira REE project in Brazil.

Neuren Pharmaceuticals and its US partner Acadia have been blitzing it with the Rett syndrome treatment Daybue.

Graphene is gaining serious traction in Europe after major funding, while in Australia, Adisyn is positioning itself as a key ...

Tony turns his attention to pivotal phase 3 trials and what mix of make or break biotechs you should have in your portfolio.

Donald Trump again has raised the prospect of a new tariff on imported pharmaceuticals, reportedly pitched at a 25% rate.

ASX nudges up on US tariff hopes, but Bellevue Gold gets hammered after a capital raise, while HUB24 shines with record inflows.

The US FDA has approved EBR System's leadless pacemaker WISE, the only heart device able to deliver left-ventricle ...

Donald Trump considers the pinnacle of his ‘Make America Great Again’ pledge a US-made iPhone. This is an unlikely outcome and here's why.

Climbing energy and gold stocks have lifted the ASX in early trading, boosting the bourse 0.3pc in the first hour.